Revolution Medicines, Inc. (RVMD) Down 8.7% — Is It Time to Lighten the Load?
Revolution Medicines, Inc. (RVMD) is under heavy pressure on Thursday, last trading at $183.36 on the NASDAQ, a $17.51 decline from the prior close of $200.87. The drop leaves the stock about 18.3% below its 52-week high of $224.31, set on August 27, 2026, and has erased a large share of the late-summer advance in just a few weeks. The broader trajectory is still extraordinary: shares remain roughly four times above the 52-week low of $45.80. That gain explains why the stock is vulnerable to sharp pullbacks.
Volume stands at roughly 1.18 million shares, about half of the 90-day average of 2.37 million, with the regular session still underway.
Why Revolution Medicines, Inc. Price is Moving Lower
The most plausible driver is a broader retreat in development-stage biotech, amplified by profit-taking in one of the group's biggest winners. The SPDR S&P Biotech ETF (XBI) was down 1.87% at 10:14 a.m. ET on Thursday. Other Health Care names are also lower, with Roivant Sciences Ltd. (ROIV) off 3.80% and BioNTech SE (BNTX) down 2.88%. The pressure on clinical-stage stocks did not start today. On October 6, the medical-development biotech group fell 3.3%, with Moderna (MRNA) dropping 7.8%, Vaxcyte (PCVX) sliding 9.7%, and RVMD giving up 3.8%. That makes Thursday's move the second leg of a sector-wide unwind rather than a reaction to new company-specific news.
RVMD's decline is far steeper than the sector's, which points to valuation sensitivity in a stock that ran from $45.80 to $224.31 inside a year. The selling has come despite constructive developments. On October 5, Revolution said it had begun treating patients in RASolute 309, a Phase 3 trial of daraxonrasib plus zoldonrasib as first-line treatment for metastatic RAS G12D pancreatic cancer. The next day, Truist nudged its price target from $239 to $240 and kept its Buy rating. Neither item changed the picture enough to stop investors from locking in gains while the group was under pressure.
The fundamental backdrop gives holders less cushion when sentiment turns. Revolution's Q2 report on August 5 showed a loss of $3.06 per share. That was well wide of the $2.04 loss analysts expected and more than double the $1.31 loss a year earlier. The net loss widened to $644.4 million from $247.8 million. Management also raised its 2026 operating-expense guidance to $2.1 billion to $2.2 billion. Rising expenses are typical for a company pushing multiple programs into registrational trials. Even so, they make the valuation depend entirely on clinical and regulatory outcomes that remain years from being reflected in revenue.
What is the Revolution Medicines, Inc. Rating - Should I Sell?
Weiss Ratings assigns RVMD a D- rating. Current recommendation is Sell. Recent results reinforce the rating. With per-share losses running at $8.81 over the trailing period and a forward P/E of -22.67, the valuation rests on a pipeline rather than on earnings. The D- reflects how much execution and regulatory risk sits between today's $42.84 billion market cap and commercial revenue.
The stock does have real strengths. Revolution is rated Excellent on the Total Return Index, which reflects a share price that roughly quadrupled from its $45.80 low before peaking in late August. Few Health Care names of this size have delivered comparable returns to holders over the measurement period. The Good rating on the Solvency Index suggests the balance sheet can support an operating budget now guided above $2 billion for 2026 without immediate financing stress. That matters for a company running a Phase 3 program in pancreatic cancer alongside several earlier-stage candidates.
The weakness shows up in the operating dimensions. The Very Weak rating on the Growth Index reflects a company with no meaningful product revenue whose losses are accelerating, as the second-quarter net loss of $644.4 million against $247.8 million a year earlier shows. The same spending explains the Very Weak Efficiency Index. Every dollar of capital is going into clinical development with no current return, and for a clinical-stage oncology developer that will remain true until a drug reaches the market. Volatility is rated Fair. That is better than many clinical-stage peers, but today's 8.72% slide, which followed a 3.8% drop on October 6 amid the biotech sell-off, shows why that rating is not higher.
Across the Health Care sector, Revolution sits alongside Moderna, Inc. (MRNA, D-) and BioNTech SE (BNTX, D-), two other companies whose valuations depend heavily on pipeline execution. Zoetis Inc. (ZTS, D) ranks slightly higher. Even that animal-health company with an established commercial base sits in Sell territory, a sign of how cautious the framework is across this group.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company in the Health Care sector. Incorporated in 2014 and headquartered in Redwood City, California, the company develops targeted therapies for RAS-addicted cancers. RAS mutations drive many of the hardest-to-treat solid tumors, including pancreatic, lung, and colorectal cancers, and drug developers have historically struggled to target them.
The pipeline is built around RAS(ON) inhibitors, which bind the active form of RAS variants. These drugs are designed to work as monotherapy, in combination with one another, or alongside companion inhibitors that suppress the pathways tumors use to sustain RAS signaling. The lead asset is daraxonrasib (RMC-6236). It is being evaluated with zoldonrasib (RMC-9805), a G12D-selective inhibitor, in a Phase 3 registrational trial in first-line metastatic pancreatic ductal adenocarcinoma. Elironrasib (RMC-6291), which targets the G12C mutation, is in early clinical development for solid tumors.
Behind those programs sits a deeper bench of mutation-specific candidates. RMC-5127, targeting G12V, and RMC-0708, targeting Q61H, are both in clinical trials, and RMC-8839, aimed at G13C, is a development candidate. Revolution's competitive position comes from the breadth of this portfolio. By building inhibitors against multiple RAS variants that can be combined with one another, the company is trying to own the RAS-driven cancer category rather than compete with a single drug.
Investor Outlook
Revolution Medicines, Inc. (RVMD) carries a Weiss Rating of D- (Sell). Today's slide shows how quickly a richly valued clinical-stage stock can give back gains when the biotech group turns lower. Investors should watch enrollment progress in RASolute 309, the next quarterly report for whether spending stays within the $2.1 billion to $2.2 billion guidance, and whether the selling in development-stage biotech stabilizes. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--